Sanuwave Health reports preliminary Q1 revenue $9.1M-$9.3M

SANUWAVE announced that revenues for the first quarter of 2025 are expected to be in the range of $9.1M to $9.3M, an increase of 57% to 61% over Q1 2024 and slightly above the upper end of the range of guidance given in the Company’s Q4 2024 earnings release issued on March 21. “Sanuwave is pleased to announce a strong start to 2025, putting up our best Q1 in Company history,” said CEO Morgan Frank. “Q1 was a transition quarter as we moved to a new head of sales and restructured the sales force. I’m very proud of the team managing this without missing a beat. Our pipeline remains robust and consistent with 2025 being a breakout year for Sanuwave. The Company plans to release its full Q1 results on or around May 9, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance. Given the current trade climate and as we have received a number of questions from investors, I’d also like to take this opportunity to clarify that all manufacturing for the UltraMIST system and its applicators is performed domestically. Sanuwave does not anticipate any significant effects on production from the current tariff situation.”